Collectively, these data reveal key insights into metabolic reprogramming events driven by FLT3 mutations in AML and suggest a novel combinatorial therapeutic strategy to enhance the targeted therapy of this aggressive subtype of AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.